← All trials
NCT05728944
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2023
- Primary completion
- Dec 14, 2023
- Completion date
- Jan 31, 2024
- First posted
- Feb 15, 2023
- Last posted
- Dec 19, 2023
- Enrollment
- 229
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Presbyopia Therapies, LLCLead sponsor
- ORA, Inc.Collaborator
- Presbyopia Therapies, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.